Unidad de Sobrepeso, Obesidad y Enfermedades Metabólicas Neuro-Salud

Unidad de Sobrepeso, Obesidad y Enfermedades Metabólicas Neuro-Salud Centro especializado en sobrepeso, obesidad y enfermedades metabolicas

19/08/2026

Short bursts of physical activity promote metabolic health better than moderate-intensity exercise

The researchers comparing different intensities of exercise found that six sets of 30-second, all-out sprints altered nearly a quarter of the proteins measured immediately afterward. Moderate, continuous cycling for 90 minutes altered fewer than one-quarter of one percent. And while moderate running on a treadmill changed more proteins than cycling, it still altered far fewer than a quick sprint.

Sprinting triggered changes in more than 200 metabolites. It also caused an immediate surge of proteins involved in blood-vessel growth, tissue remodeling, and hormonal signaling. Some of these proteins appear to enter the bloodstream through an expedited cell signaling process known as ectodomain shedding—rather than being newly made and secreted, portions of proteins already sitting on the cell surface were cleaved off and rapidly released into circulation. The researchers also found that human fat cells exposed to blood collected after sprinting underwent extensive changes in gene activity, shifting how the cells process fuel, respond to hormones, and sense nutrient availability.

Not so with moderate exercise which produced a more modest response. It was not until three hours after completing that exercise that a meaningful wave of the fatty acids and liver-derived proteins that typically appear in response to the demands of endurance exercise were found in the bloodstream. Human fat cells exposed to blood collected after moderate cycling had only minor changes in gene activity.

When the researchers compared the exercise-responsive proteins with health data from more than 53,000 people in the UK Biobank, they found that many of these proteins were associated with a lower risk of cardiovascular and metabolic disease. The connection was particularly striking for obesity, type 2 diabetes, and other metabolic disorders: of 33 proteins associated with lower risk, 32 were altered by sprinting, compared with just three by moderate exercise. More than a quarter of these proteins were also associated with slower biological aging.

https://sciencemission.com/Short-bursts-of-physical-activity

18/08/2026
12/08/2026

Patients taking preoperative receptor agonists before had similar 12-month outcomes to patients not taking these medications, despite higher rates of diabetes before surgery.

These findings suggest that preoperative GLP-1 receptor agonist treatment neither improved nor reduced early postoperative weight-loss outcomes.

https://ja.ma/4xvtZmv

12/08/2026

The size of a person’s midsection is a better indicator of cardiovascular disease risk when compared to their body mass index (BMI) alone, according to a study published in .

BMI has traditionally been used to determine overweight or obesity, common risk factors for heart disease, but this study shows that not accounting for waist circumference or waist-to-hip ratio can lead to misclassification of cardiovascular disease risk. https://bit.ly/45pIlZM

11/08/2026

📚 NOW AVAILABLE: Medical Management of Type 2 Diabetes
We're excited to announce the ninth edition of an essential clinical resource. Expert authors interpret the latest research on diagnosis and classification, management, and complications of type 2 diabetes.

This definitive update features all-new sections on hypoglycemia, obesity, and psychosocial care, as well as expanded discussions of:

✓ Diabetes education and behavior change strategies
✓ Nutrition therapy and physical activity recommendations
✓ Diabetic ketoacidosis and other acute complications
✓ Glycemic, cardiovascular, and renal benefits of pharmacological interventions
✓ Paradigm-changing diabetes technologies

In accordance with the lastest Standards of Care in Diabetes, this text provides clinicians the knowledge and skills they need to ensure optimal care for people living with this complex condition.

📖 Read individual chapters online: doi.org/10.2337/9781580408615
🛒 Purchase your printed copy: https://shopdiabetes.org/products/medical-management-of-type-2-diabetes-9th-edition

10/08/2026
10/08/2026

GLP-1s may reduce binge eating and similar behaviours in people living with obesity, suggests the most comprehensive systematic review and meta-analysis to date, published in eClinicalMedicine.

Find out more 👉 http://spkl.io/61897yUsZ

Figure: Visual summary of included studies and main findings.

26/07/2026

Evolución en el tiempo de los farmacos para el tratamiento de la Obesidad.

24/07/2026

🚨 LA NUEVA COMPETENCIA EN OBESIDAD ES ORAL: ORFORGLIPRON VS. WEGOVY®️ PILL

Dos agonistas del receptor GLP-1 administrados una vez al día, pero con diferencias importantes. Orforglipron es una molécula pequeña no peptídica que puede tomarse con o sin alimentos; en ATTAIN-1 alcanzó una reducción media de peso de hasta 12,4% a las 72 semanas bajo el estimando de eficacia.

Semaglutida oral 25 mg es un análogo peptídico que debe tomarse en ayunas, con hasta 120 mL de agua, esperando al menos 30 minutos antes de ingerir alimentos, bebidas u otros medicamentos. En OASIS 4 produjo una pérdida de peso de 16,6%, aproximadamente 17%, bajo el estimando de eficacia, a las 64 semanas.

⚠️ No es una comparación directa cabeza a cabeza. Los porcentajes provienen de ensayos diferentes, con distintas duraciones, formulaciones y estimandos. Además, ambos fármacos pueden retrasar el vaciamiento gástrico y modificar la absorción de medicamentos orales, por lo que deben revisarse posibles interacciones y tratamientos concomitantes.

¿Qué opinas? Deja tu comentario ⬇️

📚 Referencias: Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Adults with Obesity. N Engl J Med. 2025. doi:10.1056/NEJMoa2511774; Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025. doi:10.1056/NEJMoa2500969.; US Food and Drug Administration. Foundayo®️ and Wegovy®️ prescribing information. 2026.

DISCLAIMER: Información basada en evidencia científica y con fines educativos. Este contenido no sustituye la evaluación médica individual ni las recomendaciones de un profesional de la salud.

Dirección

Avenida General Proaño Y Juan Abel Echeverria
Latacunga

Notificaciones

Sé el primero en enterarse y déjanos enviarle un correo electrónico cuando Unidad de Sobrepeso, Obesidad y Enfermedades Metabólicas Neuro-Salud publique noticias y promociones. Su dirección de correo electrónico no se utilizará para ningún otro fin, y puede darse de baja en cualquier momento.

Contacto El Consultorio

Enviar un mensaje a Unidad de Sobrepeso, Obesidad y Enfermedades Metabólicas Neuro-Salud:

Atajos

Compartir

Categoría